Q-omics provides the consensus-scored CSAG3 profile across patient tissues and cancer cell-line models. CSAG3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CSAG3 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, CSAG3 RNA expression shows 6,689 significant pathway-activity associations, with the highest sampling consensus in SKCM. Together, these results highlight COAD, HNSC, and SKCM as cancer lineages where CSAG3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSAG3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSAG3 survival associations across molecular data types. CSAG3 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSAG3 RNA expression–survival associations across cancer types. High CSAG3 expression shows unfavorable associations in COAD, UVM, UCEC, LIHC and KIRC, but favorable associations in ACC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for CSAG3 RNA expression.
This table summarizes CSAG3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CSAG3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSAG3 shows lower tumor expression in KIRP and KIRC and higher tumor expression in HNSC, BLCA, BRCA and LUSC. The HNSC box plot shows higher CSAG3 RNA expression in tumor versus normal tissue (log2 FC = +2.203, t-test p < 0.001).
This table shows molecular features associated with CSAG3 in patient tissues and cancer cell lines. In patient samples, CSAG3 shows the broadest associations at the RNA and protein expression levels, with SKCM recurring as the lineage with the largest associated feature set.
